📰 Risk Evaluation News
Page 19 - Risk Evaluation News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Risk Evaluation. Real-time updates on events, politics, business and more.
September 5, 2023
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson will showcase data from its neuropsychiatry portfolio at Psych Congress 2023. The...
September 5, 2023
Brixadi® (buprenorphine) extended-release subcutaneous injection is now available for the treatment of moderate to severe opioid use disorder.
September 1, 2023
It has been two years since President Biden signed a far-reaching, industry-spanning Executive Order on Promoting Competition in the American Economy. The Executive Order outlined a...
September 1, 2023
/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...
September 1, 2023
NEW YORK, Sept. 1, 2023 /PRNewswire/ -- Delcath Systems, Inc. , an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today that it...
August 31, 2023
Advances in Videoconferencing Do Not Change the Subpoena Power of the Court - In In re Kirkland, 2023 WL 4777937 (9th Cir. July 27, 2023), the Ninth Circuit held that a...
August 28, 2023
Results from VALOR-HCM LTE demonstrated that with longer follow-up, CAMZYOS continued to reduce eligibility for invasive SRT at 56 weeks EXPLORER-LTE data showed sustained improvements in LVOT...
August 25, 2023
Polpharma Biologics Announces FDA Approval of Tyruko® -  First And Only Approved Biosimilar to Tysabri®* for Relapsing Forms of Multiple SclerosisAMSTERDAM, The Netherlands, August 25, 2023 / B3C newswire / -- Polpharma Biologics, an international biotech company dedicated to the development and ma...
August 25, 2023
The FDA is the first regulatory agency globally to approve natalizumab-sztn as a biosimilar for natalizumab.